4-Hydroxy-trans-2-nonenoic acid is γ-hydroxybutyrate receptor ligand in the cerebral cortex and lippocampus

Journal of Neurochemistry

Volumn 89, Issue 6, 2004, Pages 1462-1470

  Murphy, Tonya C ^a   Poppe, Claire ^a   Porter, James E ^a   Montine, Thomas J ^b   Picklo Sr , Matthew J ^a  

^a UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

hydroxybutyrate; 4 hydroxy 2 nonenal; Aldehyde dehydrogenases; Alzheimer's disease; Lipid peroxidation

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR BLOCKING AGENT; 4 HYDROXY 2 NONENOIC ACID; 4 HYDROXYBUTYRATE RECEPTOR; 4 HYDROXYBUTYRIC ACID; 4 HYDROXYNONENAL; ALCOHOL; ALDEHYDE; ALDEHYDE DEHYDROGENASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; LIGAND; NCS 382; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RECEPTOR; RECEPTOR BLOCKING AGENT; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; LIGAND BINDING; LIPID PEROXIDATION; MALE; METABOLITE; NONHUMAN; PRIORITY JOURNAL; RAT;

ADRENERGIC BETA-ANTAGONISTS; AGE FACTORS; ANIMALS; BENZOCYCLOHEPTENES; BINDING, COMPETITIVE; CELL MEMBRANE; CEREBRAL CORTEX; DOSE-RESPONSE RELATIONSHIP, DRUG; GABA ANTAGONISTS; HIPPOCAMPUS; HUMANS; HYDROXY ACIDS; LIGANDS; MALE; RATS; RECEPTORS, ADRENERGIC, BETA; RECEPTORS, CELL SURFACE; RECEPTORS, GABA-B;

ANIMALIA; HIPPOCAMPUS HIPPOCAMPUS;

EID: 3042695161     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2004.02442.x     Document Type: Article

References (60)

1. Andriamampandry C., Taleb O., Viry S., Muller C., Humbert J. P., Gobaille S., Aunis D. and Maitre M. (2003) Cloning and characterization of a rat brain receptor that binds the endogenous neuromodulator gamma-hydroxybutyrate (GHB). Faseb J. 17, 1691-1693.
2. Azzi M., Pineyro G., Pontier S., Parent S., Ansanay H. and Bouvier M. (2001) Allosteric effects of G protein overexpression on the binding of beta-adrenergic ligands with distinct inverse efficacies. Mol. Pharmacol. 60, 999-1007.
3. Benavides J., Rumigny J. F., Bourguignon J. J., Wermuth C. G., Mandel P. and Maitre M. (1982) A high-affinity, Na+-dependent uptake system for gamma-hydroxybutyrate in membrane vesicles prepared from rat brain. J. Neurochem. 38, 1570-1575.
4. Blanc E. M., Kelly J. F., Mark R. J., Waeg G. and Mattson M. P. (1997) 4-Hydroxynonenal, an aldehydic product of lipid peroxidation, impairs signal transduction associated with muscarinic acetylcholine and metabotropic glutamate receptors: possible action on G alpha(q/11). J. Neurochem. 69, 570-580.
5. Blanc E. M., Keller J. N., Fernandez S. and Mattson M. P. (1998) 4-hydroxynonenal, a lipid peroxidation product, impairs glutamate transport in cortical astrocytes. Glia 22, 149-160.
6. Calon F., Lavertu N., Lemieux A. M., Morissette M., Goulet M., Grondin R., Blanchet P. J., Bedard P. J. and Di Paolo T. (2001) Effect of MPTP-induced denervation on basal ganglia GABA(B) receptors: Correlation with dopamine concentrations and dopamine transporter. Synapse 40, 225-234.
7. Camandola S., Poli G. and Mattson M. P. (2000) The lipid peroxidation product 4-hydroxy-2,3-nonenal inhibits constitutive and inducible activity of nuclear factor kappa B in neurons. Brain Res. Mol. Brain Res. 85, 53-60.
8. Carai M. A., Colombo G., Brunetti G. et al. (2001) Role of GABA(B) receptors in the sedative/hypnotic effect of gamma-hydroxybutyric acid. Eur. J. Pharmacol. 428, 315-321.
9. Castelli M. P., Mocci I., Langlois X., Gommerendagger W., Luyten W. H., Leysen J. E. and Gessa G. L. (2000) Quantitative autoradiographic distribution of gamma-hydroxybutyric acid binding sites in human and monkey brain. Brain Res. Mol. Brain Res. 78, 91-99.
10. Castelli M. P., Mocci I., Pistis M., Peis M., Berta D., Gelain A., Gessa G. L. and Cignarella G. (2002) Stereoselectivity of NCS-382 binding to gamma-hydroxybutyrate receptor in the rat brain. Eur. J. Pharmacol. 446, 1-5.
11. Castelli M. P., Ferraro L., Mocci I., Carta F., Carai M. A., Antonelli T., Tanganelli S., Cignarella G. and Gessa G. L. (2003) Selective gamma-hydroxybutyric acid receptor ligands increase extracellular glutamate in the hippocampus, but fail to activate G protein and to produce the sedative/hypnotic effect of gamma-hydroxybutyric acid. J. Neurochem. 87, 722-732.
12. Esterbauer H., Cheeseman K. H., Dianzani M. U., Poli G. and Slater T. F. (1982) Separation and characterization of the aldehydic products of lipid peroxidation stimulated by ADP-Fe2+ in rat liver microsomes. Biochem. J. 208, 129-140.
13. Esterbauer H., Schaur R. and Zollner H. (1991) Chemistry and biochemistry of 4-hydroxynonenal, malondialdehyde, and related aldehydes. Free Radic. Biol. Med. 11, 81-128.
14. Ferraro L., Tanganelli S., O'Connor W. T., Francesconi W., Loche A., Gessa G. L. and Antonelli T. (2001) Gamma-hydroxybutyrate modulation of glutamate levels in the hippocampus: an in vivo and in vitro study. J. Neurochem. 78, 929-939.
15. Gibson K. M., Sweetman L., Nyhan W. L. and Rating D. (1984) Succinic semialdehyde dehydrogenase deficiency. J. Neurogenet. 1, 213-218.
16. Gibson K. M., Nyhan W. L. and Jaeken J. (1986) Inborn errors of GABA metabolism. Bioessays 4, 24-27.
17. Grunewald S., Schupp B. J., Ikeda S. R., Kuner R., Steigerwald F., Kornau H. C. and Kohr G. (2002) Importance of the gamma-aminobutyric acid(B) receptor C-termini for G-protein coupling. Mol. Pharmacol. 61, 1070-1080.
18. Ji C., Kozak K. R. and Marnett L. J. (2001) IkappaB kinase, a molecular target for inhibition by 4-hydroxy-2-nonenal. J. Biol. Chem. 276, 18223-18228.
19. Kemmel V., Taleb O., Perard A., Andriamampandry C., Siffert J. C., Mark J. and Maitre M. (1998) Neurochemical and electrophysiological evidence for the existence of a functional gamma-hydroxybutyrate system in NCB-20 neurons. Neuroscience 86, 989-1000.
20. Kruman I., Bruce-Keller A. J., Bredesen D., Waeg G. and Mattson M. P. (1997) Evidence that 4-hydroxynonenal mediates oxidative stress-induced neuronal apoptosis. J. Neurosci. 17, 5089-5100.
21. Kumagai T., Kawamoto Y., Nakamura Y., Hatayama I., Satoh K., Osawa T. and Uchida K. (2000) 4-hydroxy-2-nonenal, the end product of lipid peroxidation, is a specific inducer of cyclooxygenase-2 gene expression. Biochem. Biophys. Res. Commun. 273, 437-441.
22. Kunapuli P., Lawson J. A., Rokach J. A., Meinkoth J. L. and FitzGerald G. A. (1998) Prostaglandin F2alpha (PGF2alpha) and the isoprostane, 8, 12-iso-isoprostane F2alpha-III, induce cardiomyocyte hypertrophy. Differential activation of downstream signaling pathways. J. Biol. Chem. 273, 22442-22452.
23. Laurent A., Perdu-Durand E., Alary J., Debrauwer L. and Cravedi J. P. (2000) Metabolism of 4-hydroxynonenal, a cytotoxic product of lipid peroxidation, in rat precision-cut liver slices. Toxicol. Lett. 114, 203-214.
24. Limbird L. E. (1996) Identification of receptors using direct radioligand binding techniques. In: Cell Surface Receptors: a Short Course on Theory and Methods, 2nd Edn, pp. 61-119. Kluwer Academic, Boston.
25. Lindahl R. and Petersen D. R. (1991) Lipid aldehyde oxidation as a physiological role for class 3 aldehdye dehyrdogenases. Biochem. Pharmacol. 41, 1583-1587.
26. Lingenhoehl K., Brom R., Heid J., Beck P., Froestl W., Kaupmann K., Bettler B. and Mosbacher J. (1999) Gamma-hydroxybutyrate is a weak agonist at recombinant GABA(B) receptors. Neuropharmacology 38, 1667-1673.
27. Liu W., Akhand A. A., Kato M., Yokoyama I., Miyata T., Kurokawa K., Uchida K. and Nakashima I. (1999) 4-hydroxynonenal triggers an epidermal growth factor receptor-linked signal pathway for growth inhibition. J. Cell Sci 112, 2409-2417.
28. Lovell M. A., Ehmann W. D., Mattson M. P. and Markesbery W. R. (1997) Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer's disease. Neurobiol. Aging 18, 457-461.
29. Markesbery, W. R. and Lovell M. A. (1998) Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol. Aging 19, 33-36.
30. Mattson M. P., Fu W., Waeg G. and Uchida K. (1997) 4-Hydroxynonenal, a product of lipid peroxidation, inhibits dephosphorylation of the microtubule-associated protein tau. Neuroreport 8, 2275-2281.
31. McKracken E., Graham D. I., Nilsen M., Stewart J., Nicoll J. A. and Horsburgh K. (2001) 4-Hydroxynonenal immunoreactivity is increased in human hippocampus after global ischemia. Brain Pathol. 11, 414-421.
32. Mehta A. K., Muschaweck N. M., Maeda D. Y., Coop A. and Ticku M. K. (2001) Binding characteristics of the gamma-hydroxybutyric acid receptor antagonist [(3)H](2E)-(5-hydroxy-5,7,8,9-tetrahydro-6H-benzo[a][7]annulen-6- ylidene) ethanoic acid in the rat brain. J. Pharmacol. Exp. Ther. 299, 1148-1153.
33. Mitchell D. and Petersen D. (1987) The oxidation of a,b,unsaturated aldehydic products in lipid peroxidation by rat liver aldehyde dehydrogenases. Toxicol. Appl. Pharmacol. 87, 403-410.
34. Mohler E. R., Franklin M. T. and Adam L. P. (1996) Intracellular signaling by 8-epi-prostaglandin F2 alpha is mediated by thromboxane A2/prostaglandin endoperoxide receptors in porcine carotid arteries. Biochem. Biophys. Res. Commun. 225, 915-923.
35. Montine K. S., Olson S. J., Amarnath V., Whetsell W. O. Jr, Graham D. G. and Montine T. J. (1997) Immunohistochemical detection of 4-hydroxy-2-nonenal adducts in Alzheimer's disease is associated with inheritance of APOE4. Am. J. Pathol. 150, 437-443.
36. 2-isoprostanes) in carbon tetrachloride hepatotoxicity. J. Clin. Invest. 90, 2502-2507.
37. Morrow J. D., Tapper A. R., Zackert W. E., Yang J.; Sanchez S. C., Montine T. J. and Roberts L. J. (1999) Formation of novel isoprostane-like compounds from docosahexaenoic acid. Adv. Exp. Med. Biol. 469, 343-347.
38. Murphy T., Amarnath V. and Picklo M. J. (2003a) Oxidation of 4-hydroxynonenal in rat brain slices. Chem. Biol. Interact. 143-144, 101-105.
39. Murphy T. C., Amarnath V. and Picklo M. J. S. (2003b) Mitochondrial oxidation of 4-hydroxynonenal in rat cerebral cortex. J. Neurochem. 84, 1313-1321.
40. Murphy T. C., Amarnath V., Gibson K. M. and Picklo M. J. S. (2003c) Oxidation of 4-hydroxy-2-nonenal by succinic semialdehyde dehydrogenase (ALDH5A). J. Neurochem. 86, 298-305.
41. Neely M. D., Sidell K. R., Graham D. G. and Montine T. J. (1999) The lipid peroxidation product 4-hydroxynonenal inhibits neurite outgrowth, disrupts neuronal microtubules, and modifies cellular tubulin. J. Neurochem. 72, 2323-2333.
42. Nguyen E. and Picklo M. J. (2003) Inhibition of succinic semialdehyde dehydrogenase activity by alkenal products of lipid peroxidation. Biochim. Biophys. Acta 1637, 107-112.
43. Picklo M. J., Amarnath V., McIntyre J. O., Graham D. G. and Montine T. J. (1999) 4-Hydroxy-2(E)-nonenal inhibits CNS mitochondrial respiration at multiple sites. J. Neurochem. 72, 1617-1624.
44. Picklo M. J. Sr, Olson S. J., Hayes J. D., Markesbery W. R. and Montine T. J. (2001) Elevation of AKR7A2 (succinic semialdehyde reductase) in neurodegenerative disease. Brain Res. 916, 229-238.
45. Picklo M. J., Montine T. J., Amarnath V. and Neely M. D. (2002) Carbonyl toxicology and Alzheimer's disease. Toxicol. Appl. Pharmacol. 184, 187-197.
46. Porter J. E. and Perez D. M. (1999) Characteristics for a salt-bridge switch mutation of the alpha(1b) adrenergic receptor. Altered pharmacology and rescue of constitutive activity. J. Biol. Chem. 274, 34535-34538.
47. Roberts L. J. 2nd, Montine T. J., Markesbery W. R., Tapper A. R., Hardy P., Chemtob S., Dettbarn W. D. and Morrow J. D. (1998) Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid. J. Biol. Chem. 273, 13605-13612.
48. Roberts L. J. 2nd, Salomon R. G., Morrow J. D. and Brame C. J. (1999) New developments in the isoprostane pathway: identification of novel highly reactive gamma-ketoaldehydes (isolevuglandins) and characterization of their protein adducts. Faseb J. 13, 1157-1168.
49. Sato S., Sato N., Kudej R. K., Uechi M., Asai K., Shen Y. T., Ishikawa Y., Vatner S. F. and Vatner D. E. (1997) Beta-adrenergic receptor signaling in stunned myocardium of conscious pigs. J Mol. Cell Cardiol. 29, 1387-1400.
50. Selley M. (1998) (E)-4-Hydroxynonenal may be involved in the pathogenesis of Parkinson's disease. Free Radic. Biol. Med. 25, 169-174.
51. Shin Y., White B. H., Uh M. and Sidhu A. (2003) Modulation of D1-like dopamine receptor function by aldehydic products of lipid peroxidation. Brain Res. 968, 102-113.
52. Sidell K. R., Montine K. S., Picklo M. J. Sr, Olsen S. J., Amarnath V. and Montine T. J. (2003) Mercapturate metabolism of 4-hydroxy-2-nonenal in rat and human cerebrum. J. Neuropathol. Exp. Neurol. 62, 146-153.
53. Snead O. C. (2000) Evidence for a G protein-coupled gamma-hydroxybutyric acid receptor. J. Neurochem. 75, 1986-1996.
54. Soh Y., Jeong K. S., Lee I. J., Bae M. A., Kim Y. C. and Song B. J. (2000) Selective activation of the c-Jun N-terminal protein kinase pathway during 4-hydroxynonenal-induced apoptosis of PC12 cells. Mol. Pharmacol. 58, 535-541.
55. Song B. J., Soh Y., Bae M., Pie J., Wan J. and Jeong K. (2001) Apoptosis of PC12 cells by 4-hydroxy-2-nonenal is mediated through selective activation of the c-Jun N-terminal protein kinase pathway. Chem. Biol. Interact. 130-132, 943-954.
56. Srivastava S., Chandra A., Wang L. F., Seifert W. E. Jr, DaGue B. B., Ansari N. H., Srivastava S. K. and Bhatnagar A. (1998) Metabolism of the lipid peroxidation product, 4-hydroxy-trans-2-nonenal, in isolated perfused rat heart. J. Biol. Chem. 273, 10893-10900.
57. Srivastava S., Dixit B. L., Cai J., Sharma S., Hurst H. E., Bhatnagar A. and Srivastava S. K. (2000) Metabolism of lipid peroxidation product, 4-hydroxynonenal (HNE) in rat erythrocytes: role of aldose reductase. Free Radic. Biol. Med. 29, 642-651.
58. Tazzeo T., Miller J. and Janssen L. J. (2003) Vasoconstrictor responses, and underlying mechanisms, to isoprostanes in human and porcine bronchial arterial smooth muscle. Br. J. Pharmacol. 140, 759-763.
59. Uchida K., Shiraishi M., Naito Y., Torii Y., Nakamura Y. and Osawa T. (1999) Activation of stress signaling pathways by the end product of lipid peroxidation. 4-hydroxy-2-nonenal is a potential inducer of intracellular peroxide production. J. Biol. Chem. 274, 2234-2242.
60. Weber T. J. and Markillie L. M. (2003) Regulation of activator protein-1 by 8-iso-prostaglandin E2 in a thromboxane A2 receptor-dependent and -independent manner. Mol. Pharmacol. 63, 1075-1081.